Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 8 | 2025 | 896 | 2.430 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2024 | 630 | 1.920 |
Why?
|
| Bronchoscopy | 4 | 2019 | 179 | 1.160 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2025 | 126 | 1.140 |
Why?
|
| Patient Outcome Assessment | 2 | 2020 | 92 | 1.060 |
Why?
|
| Shock, Septic | 3 | 2025 | 147 | 1.010 |
Why?
|
| Noninvasive Ventilation | 3 | 2019 | 32 | 0.880 |
Why?
|
| Betacoronavirus | 3 | 2020 | 285 | 0.780 |
Why?
|
| Bronchodilator Agents | 1 | 2024 | 153 | 0.770 |
Why?
|
| Positive-Pressure Respiration | 2 | 2019 | 83 | 0.750 |
Why?
|
| Respiration, Artificial | 4 | 2020 | 489 | 0.690 |
Why?
|
| Smoking | 3 | 2022 | 904 | 0.690 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 363 | 0.690 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 375 | 0.690 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2020 | 22 | 0.660 |
Why?
|
| Intensive Care Units | 4 | 2019 | 497 | 0.640 |
Why?
|
| Symptom Flare Up | 1 | 2019 | 25 | 0.630 |
Why?
|
| Hepatitis B, Chronic | 1 | 2021 | 87 | 0.630 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1867 | 0.600 |
Why?
|
| Fever | 2 | 2020 | 309 | 0.600 |
Why?
|
| Dengue | 1 | 2020 | 120 | 0.600 |
Why?
|
| Legionellosis | 1 | 2018 | 4 | 0.590 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2018 | 15 | 0.580 |
Why?
|
| Stroke | 3 | 2023 | 1028 | 0.560 |
Why?
|
| Glomerulonephritis | 1 | 2018 | 75 | 0.550 |
Why?
|
| Fungemia | 1 | 2017 | 21 | 0.550 |
Why?
|
| Lung Neoplasms | 3 | 2019 | 1494 | 0.530 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 112 | 0.520 |
Why?
|
| Candidiasis | 1 | 2017 | 128 | 0.500 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 198 | 0.490 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 30 | 0.490 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2016 | 21 | 0.490 |
Why?
|
| Inpatients | 1 | 2020 | 540 | 0.490 |
Why?
|
| HIV Infections | 2 | 2019 | 1954 | 0.480 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 81 | 0.480 |
Why?
|
| Pneumothorax | 1 | 2016 | 82 | 0.470 |
Why?
|
| Pulmonary Embolism | 1 | 2018 | 184 | 0.470 |
Why?
|
| Hospital Mortality | 4 | 2025 | 1047 | 0.470 |
Why?
|
| Hemorrhage | 2 | 2020 | 492 | 0.470 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 235 | 0.460 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 57 | 0.460 |
Why?
|
| Esophagitis | 1 | 2015 | 38 | 0.460 |
Why?
|
| Humans | 35 | 2025 | 127099 | 0.450 |
Why?
|
| Acute Lung Injury | 1 | 2015 | 64 | 0.450 |
Why?
|
| Shock, Hemorrhagic | 1 | 2015 | 51 | 0.450 |
Why?
|
| Sarcoma, Kaposi | 1 | 2016 | 123 | 0.440 |
Why?
|
| Hepatic Encephalopathy | 1 | 2015 | 81 | 0.440 |
Why?
|
| Intracranial Thrombosis | 1 | 2014 | 12 | 0.430 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 321 | 0.430 |
Why?
|
| Lung Diseases | 1 | 2018 | 395 | 0.430 |
Why?
|
| Streptococcus agalactiae | 1 | 2015 | 102 | 0.430 |
Why?
|
| Factor VIIa | 1 | 2014 | 22 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2519 | 0.420 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 236 | 0.420 |
Why?
|
| Abscess | 1 | 2015 | 138 | 0.420 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 182 | 0.420 |
Why?
|
| Patient Admission | 3 | 2020 | 181 | 0.410 |
Why?
|
| Hemophilia A | 1 | 2014 | 25 | 0.410 |
Why?
|
| Fluid Therapy | 1 | 2014 | 143 | 0.410 |
Why?
|
| Postoperative Complications | 2 | 2016 | 3074 | 0.410 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 61 | 0.410 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 59 | 0.400 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 225 | 0.400 |
Why?
|
| Hematoma | 1 | 2014 | 89 | 0.400 |
Why?
|
| Peptide Fragments | 1 | 2017 | 756 | 0.400 |
Why?
|
| Lung | 3 | 2019 | 1522 | 0.400 |
Why?
|
| Neck | 1 | 2014 | 141 | 0.390 |
Why?
|
| Biological Products | 2 | 2025 | 138 | 0.390 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 265 | 0.390 |
Why?
|
| Streptococcal Infections | 1 | 2015 | 247 | 0.380 |
Why?
|
| Face | 1 | 2014 | 193 | 0.380 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 197 | 0.370 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 968 | 0.370 |
Why?
|
| Resuscitation | 1 | 2014 | 267 | 0.370 |
Why?
|
| Lymph Nodes | 1 | 2014 | 374 | 0.360 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 215 | 0.360 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 453 | 0.360 |
Why?
|
| Male | 20 | 2025 | 62658 | 0.350 |
Why?
|
| Coronary Artery Bypass | 1 | 2015 | 525 | 0.350 |
Why?
|
| Middle Aged | 14 | 2025 | 27801 | 0.330 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 1350 | 0.330 |
Why?
|
| Aged | 14 | 2025 | 20431 | 0.330 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2036 | 0.320 |
Why?
|
| Sepsis | 1 | 2014 | 494 | 0.320 |
Why?
|
| Female | 20 | 2025 | 68483 | 0.300 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 875 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 744 | 0.280 |
Why?
|
| Biopsy | 3 | 2016 | 1237 | 0.270 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 1140 | 0.250 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 6695 | 0.240 |
Why?
|
| Retrospective Studies | 9 | 2025 | 17065 | 0.220 |
Why?
|
| Phenotype | 3 | 2023 | 4306 | 0.220 |
Why?
|
| Length of Stay | 3 | 2020 | 1378 | 0.220 |
Why?
|
| Disease Progression | 2 | 2023 | 2118 | 0.220 |
Why?
|
| Safety-net Providers | 1 | 2025 | 64 | 0.210 |
Why?
|
| New York City | 2 | 2020 | 63 | 0.210 |
Why?
|
| Administration, Inhalation | 1 | 2024 | 187 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 542 | 0.200 |
Why?
|
| Doxycycline | 1 | 2023 | 119 | 0.190 |
Why?
|
| Sputum | 1 | 2023 | 117 | 0.190 |
Why?
|
| Biological Factors | 1 | 2022 | 26 | 0.190 |
Why?
|
| Eosinophils | 1 | 2023 | 123 | 0.190 |
Why?
|
| Inflammation | 2 | 2023 | 1433 | 0.180 |
Why?
|
| Respiratory System | 1 | 2022 | 94 | 0.180 |
Why?
|
| Incidence | 2 | 2020 | 3259 | 0.180 |
Why?
|
| May-Thurner Syndrome | 1 | 2021 | 4 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2025 | 267 | 0.180 |
Why?
|
| Adult | 8 | 2025 | 30435 | 0.180 |
Why?
|
| Neutrophils | 1 | 2023 | 355 | 0.170 |
Why?
|
| Prognosis | 3 | 2020 | 4799 | 0.170 |
Why?
|
| Gingiva | 1 | 2020 | 11 | 0.170 |
Why?
|
| Thromboembolism | 1 | 2020 | 90 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 490 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 168 | 0.160 |
Why?
|
| Pulmonary Atelectasis | 1 | 2019 | 13 | 0.160 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1595 | 0.160 |
Why?
|
| Conservative Treatment | 1 | 2019 | 38 | 0.150 |
Why?
|
| Travel | 1 | 2020 | 123 | 0.150 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 176 | 0.150 |
Why?
|
| Legionella pneumophila | 1 | 2018 | 6 | 0.150 |
Why?
|
| Pandemics | 3 | 2020 | 1140 | 0.150 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2018 | 13 | 0.150 |
Why?
|
| Bronchiectasis | 1 | 2018 | 22 | 0.140 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 31 | 0.140 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 148 | 0.140 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 210 | 0.140 |
Why?
|
| Lipopeptides | 1 | 2017 | 33 | 0.140 |
Why?
|
| Echinocandins | 1 | 2017 | 42 | 0.130 |
Why?
|
| Pulmonary Alveoli | 1 | 2018 | 137 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2020 | 1498 | 0.130 |
Why?
|
| Glioblastoma | 1 | 2020 | 335 | 0.130 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 2991 | 0.130 |
Why?
|
| Coinfection | 1 | 2018 | 185 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 209 | 0.130 |
Why?
|
| Risk Factors | 3 | 2020 | 10610 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2048 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2020 | 581 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2020 | 1194 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 503 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2233 | 0.120 |
Why?
|
| Antifungal Agents | 1 | 2017 | 296 | 0.110 |
Why?
|
| Sternum | 1 | 2015 | 50 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 1484 | 0.110 |
Why?
|
| Hospitalization | 2 | 2020 | 1879 | 0.110 |
Why?
|
| Antigens, Viral | 1 | 2016 | 392 | 0.110 |
Why?
|
| Certolizumab Pegol | 1 | 2014 | 8 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2017 | 827 | 0.110 |
Why?
|
| Tracheostomy | 1 | 2017 | 215 | 0.110 |
Why?
|
| Chest Pain | 1 | 2015 | 124 | 0.110 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 59 | 0.110 |
Why?
|
| Ecchymosis | 1 | 2014 | 12 | 0.110 |
Why?
|
| Facial Pain | 1 | 2014 | 9 | 0.110 |
Why?
|
| Mercaptopurine | 1 | 2014 | 72 | 0.110 |
Why?
|
| Mediastinum | 1 | 2014 | 47 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 230 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2071 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 753 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 150 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 240 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 296 | 0.090 |
Why?
|
| Biomarkers | 2 | 2020 | 3233 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 1235 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12567 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 73 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2015 | 936 | 0.080 |
Why?
|
| Echocardiography | 1 | 2016 | 1115 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1205 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 654 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3322 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3714 | 0.070 |
Why?
|
| Hospitals, Community | 2 | 2020 | 51 | 0.060 |
Why?
|
| United States | 3 | 2025 | 11386 | 0.060 |
Why?
|
| Iliac Vein | 1 | 2021 | 28 | 0.040 |
Why?
|
| Femoral Vein | 1 | 2021 | 49 | 0.040 |
Why?
|
| Iliac Artery | 1 | 2021 | 64 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 39 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 64 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 99 | 0.040 |
Why?
|
| Comorbidity | 1 | 2025 | 1562 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 223 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 251 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 1324 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 382 | 0.040 |
Why?
|
| Cerebellum | 1 | 2020 | 414 | 0.030 |
Why?
|
| Texas | 1 | 2025 | 3563 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 4972 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2799 | 0.030 |
Why?
|
| APACHE | 1 | 2011 | 50 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 3588 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 429 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 560 | 0.020 |
Why?
|
| Vitamin D | 1 | 2011 | 180 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 587 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 946 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6142 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 249 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1788 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1026 | 0.020 |
Why?
|